Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015156 | 0.89 | PDK1 (0.51) | PDK1LMNAXDHRORCPOLB | |
| SCHEMBL1787616 | 0.86 | MEN1 (0.50) | PDK1LMNAPOLBMAPTMEN1 | |
| SCHEMBL11778508 | 0.84 | LMNA (0.53) | LMNAPOLBGAAMAPTMEN1 | |
| SCHEMBL29236565 | 0.83 | PDK1 (0.52) | PDK1LMNAXDHRORCMAPT | |
| SCHEMBL27496659 | 0.82 | PDK1 (0.51) | PDK1LMNAXDHRORCPOLB | |
| SCHEMBL1018361 | 0.79 | PDK1 (0.49) | PDK1LMNAXDHPOLBMEN1 | |
| SCHEMBL30640841 | 0.79 | PDK1 (0.49) | PDK1LMNAXDHPOLBMEN1 | |
| SCHEMBL10483678 | 0.78 | VCAM1 (0.46) | KMT2ACA12CA9VCAM1ALDH1A1 | |
| SCHEMBL27496999 | 0.77 | PDK1 (0.49) | PDK1LMNACA12CA9VCAM1 | |
| SCHEMBL24718245 | 0.77 | PDK1 (0.50) | PDK1LMNAXDHPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | disclosed |
| EP-2091918-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2014-08-27 | — | — | EP | disclosed |
| CN-102131788-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2014-03-19 | — | — | CN | disclosed |
| CN-103641816-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2014-03-19 | — | — | CN | disclosed |
| US-8592432-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| US-8399450-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-03-19 | — | — | US | disclosed |
| US-8377921-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-02-19 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| CN-102131788-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2011-07-20 | — | — | CN | disclosed |
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-06-09 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| CN-101616895-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2009-12-30 | — | — | CN | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| EP-2091918-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-08-26 | — | — | EP | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135668-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ROS1, INSR, IGF1R | PDK1 95/4885LMNA 1726/4885XDH 2369/4885 |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | PDK1 123/4885LMNA 3782/4885XDH 4145/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | PDK1 123/4885LMNA 3782/4885XDH 4145/4885 |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | PDK1 123/4885LMNA 3782/4885XDH 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.